GALNT14 gene

Known as: UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 14, polypeptide N-acetylgalactosaminyltransferase 14, polypeptide GalNAc transferase 14 
 

Topic mentions per year

Topic mentions per year

2007-2018
02420072018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND Most eukaryotic proteins are modified by covalent addition of glycan molecules that considerably influence their… (More)
Is this relevant?
2016
2016
AIM Transcatheter arterial chemoembolization is currently the standard treatment in hepatocellular carcinoma patients with… (More)
Is this relevant?
2016
2016
Some polypeptide N-acetyl-galactosaminyltransferases (GALNTs) are associated with cancer, but their function in organ-specific… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Aberrant glycosylation is a hallmark of most human cancers and affects many cellular properties, including cell proliferation… (More)
Is this relevant?
2015
2015
Although several genes have been associated to neuroblastoma (NB) predisposition and aggressiveness, further genes are likely… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Identifying genetic variants that lead to discernible phenotypes is the core of Mendelian genetics. An approach that considers… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2014
2014
In addition to targeted agents, chemotherapy is currently considered to be a treatment option for patients with advanced… (More)
Is this relevant?
2012
2012
BACKGROUND Otitis media (OM) is a common childhood disease characterised by middle ear inflammation and effusion. Susceptibility… (More)
Is this relevant?
2011
2011
AIM Despite the availability of targeted anticancer agents, combination chemotherapy remains an option for patients with far… (More)
Is this relevant?
2010
2010
PURPOSE In vitro sensitivity to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?